ストックスクリーナーアプリを入手
0.00
100.00%
-4.85
前日終値:
$4.85
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$242.51M
収益：
-
当期純損益:
-
株価収益率:
0.00
EPS:
-0.7341
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$4.9292
Genfit Adr Stock (GNFT) Company Profile
Compare GNFT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
0.00 | 242.51M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
438.81 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.93 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.98 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
311.58 | 34.24B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-19 | 再開されました | H.C. Wainwright | Buy |
| 2021-12-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | アップグレード | Stifel | Hold → Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Underperform |
| 2020-05-13 | ダウングレード | Kepler | Buy → Reduce |
| 2020-05-12 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-05-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | 繰り返されました | B. Riley FBR | Buy |
| 2019-06-25 | 開始されました | Stifel | Hold |
| 2019-04-24 | 開始されました | SVB Leerink | Outperform |
| 2019-04-22 | 開始されました | Barclays | Overweight |
すべてを表示
Genfit Adr (GNFT) 最新ニュース
GENFIT signe un partenariat de recherche avec EVerZom pour faire progresser une technologie de médecine régénérative basée sur les exosomes dans l’ACLF - GlobeNewswire Inc.
GENFIT to Delist from Nasdaq, Focuses on Euronext Paris - TipRanks
European ADRs Start The Week With Small Gains Stateside - Finimize
FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright - Defense World
HC Wainwright Has Pessimistic View of GENFIT FY2025 Earnings - MarketBeat
GENFIT (NASDAQ:GNFT) Price Target Lowered to $7.00 at HC Wainwright - Defense World
HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price - MarketBeat
European ADRs Tick Up As Pharma And Telecom Lead Gains - Finimize
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
symbol__ Stock Quote Price and Forecast - CNN
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Exclusive Licensing Agreement with GENFIT | Ipsen Global - Ipsen
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
GNFT Stock Price and Chart — EURONEXT:GNFT - TradingView
The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug - Yahoo Finance
Should I buy GENFIT (GNFT) - Zacks Investment Research
GNFT: GENFITFull Company Report - Zacks Investment Research
GNFT Stock Price | Genfit S.A. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Genfit Adr (GNFT) 財務データ
Genfit Adr (GNFT) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.34%
0.85%
大文字化:
|
ボリューム (24 時間):